AIM: The development of vaccines against Trypanosoma cruzi remains in an exploratory stage. Despite several antigen candidates have been evaluated, a comparison among the performance of the immunogens cannot be carried out because the available reports differ in formulations and infection model. In this work, we compared the protective capacity of seven T. cruzi antigens in the same model of five new antigens and two well-established candidates. Materials & methods: We evaluated highly immunogenic proteins that contain tandem repeats (FRA [flagelar repetitive protein], Tc3, Tc6); enzymes involved in metabolic pathways critical for parasite survival (cytosolic tryparedoxin peroxidase and tryparedoxin peroxidase); and enzymes involved in parasite invasion (trans-sialidase [TS] and cruzipain). All these antigens were formulated with Freund's adjuvant and protection against the parasite infection was assessed in BALB/c mice. RESULTS: Tc3, cytosolic tryparedoxin peroxidase, cruzipain and TS showed the best outcome after infection in survival level and parasitemia. According to these data, these groups were also assessed using the ISCOMATRIX™ adjuvant which is being used in clinical trials. CONCLUSION: Taken together, our results showed that the TS overcomes the performance of other antigens when the same model is employed, confirming that TS is a promising antigen that could be used as a vaccine against T. cruzi.
AIM: The development of vaccines against Trypanosoma cruzi remains in an exploratory stage. Despite several antigen candidates have been evaluated, a comparison among the performance of the immunogens cannot be carried out because the available reports differ in formulations and infection model. In this work, we compared the protective capacity of seven T. cruzi antigens in the same model of five new antigens and two well-established candidates. Materials & methods: We evaluated highly immunogenic proteins that contain tandem repeats (FRA [flagelar repetitive protein], Tc3, Tc6); enzymes involved in metabolic pathways critical for parasite survival (cytosolic tryparedoxin peroxidase and tryparedoxin peroxidase); and enzymes involved in parasite invasion (trans-sialidase [TS] and cruzipain). All these antigens were formulated with Freund's adjuvant and protection against the parasite infection was assessed in BALB/c mice. RESULTS: Tc3, cytosolic tryparedoxin peroxidase, cruzipain and TS showed the best outcome after infection in survival level and parasitemia. According to these data, these groups were also assessed using the ISCOMATRIX™ adjuvant which is being used in clinical trials. CONCLUSION: Taken together, our results showed that the TS overcomes the performance of other antigens when the same model is employed, confirming that TS is a promising antigen that could be used as a vaccine against T. cruzi.
Authors: Magalí C Girard; Gonzalo R Acevedo; Lucía López; Micaela S Ossowski; María D Piñeyro; Juan P Grosso; Marisa Fernandez; Yolanda Hernández Vasquez; Carlos Robello; Karina A Gómez Journal: Immunology Date: 2018-08-03 Impact factor: 7.397
Authors: I Bontempi; K Leal; E Prochetto; G Díaz; G Cabrera; A Bortolotti; H R Morbidoni; S Borsuk; O Dellagostin; I Marcipar Journal: Clin Exp Immunol Date: 2020-07-06 Impact factor: 4.330
Authors: Lucas D Caeiro; Catalina D Alba-Soto; Mariana Rizzi; María Elisa Solana; Giselle Rodriguez; Agustina M Chidichimo; Matías E Rodriguez; Daniel O Sánchez; Gabriela V Levy; Valeria Tekiel Journal: PLoS Negl Trop Dis Date: 2018-05-04
Authors: Ingrid Quintana; Martín Espariz; Silvina R Villar; Florencia B González; Maria F Pacini; Gabriel Cabrera; Iván Bontempi; Estefanía Prochetto; Jörg Stülke; Ana R Perez; Iván Marcipar; Victor Blancato; Christian Magni Journal: Front Microbiol Date: 2018-09-04 Impact factor: 5.640